Stay updated with breaking news from Refractory Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data presented at ASH 2021 congress show 83 percent of patients achieved a stringent complete response at median follow-up of 22 months1 92 percent of evaluable patients achieved minimal residual
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating...
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human...